ClinicalTrials.gg
RecruitingNCT04012658Updated Sep 23, 2019

A Registered Cohort Study on Wilson's Disease

An observational study in Wilson's Disease, sponsored by Wan-Jin Chen. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2019-09-23.

Sponsored by Wan-Jin Chen · Observational

How we know

From the registry’s dates

  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hepatolenticular Degeneration with a site in China — 10 open to participants now, 11 under way, 1 of them phase 3. Hepatolenticular Degeneration · China.

Started
2019
with 1 other
Observational
6 of 15
4 open now
Primary completion
2039-12
later than 10 of 10 live
Registered
4th of 15
by date

Among the 15 studies in Hepatolenticular Degeneration with a site in China, this one is one of 2 that started in 2019, is one of 6 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 4th registered.

Hepatolenticular Degeneration

80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.

Browse Hepatolenticular Degeneration studies →

Open to participants now

10 of the 15 studies in Hepatolenticular Degeneration with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hepatolenticular Degeneration with a site in China, or all of them as a file.
02

Study summary

The aim of this study is to determine the clinical spectrum and natural progression of Wilson's Disease in a prospective multicenter natural history study, to assess the clinical, genetic, epigenetic features and biomarkers of patients with Wilson's Disease to optimize clinical management.

03

Conditions studied

  • Wilson's Disease

Keywords

  • Wilson's Disease
  • Nature history
  • Genetics
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with Wilson's Disease are diagnosed by the clinical and/or genetic features

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with the genetic diagnosis of Wilson's Disease
  • Asymptomatic Wilson's Disease carriers
  • Relatives of Wilson's Disease patients or carriers
  • Unrelated healthy controls
  • Participants or Parent(s)/legal guardian(s) willing and able to complete the process

Exclusion criteria

Exclusion Criteria:

* Participants are unable to comply with study procedures and visit schedule

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with the genetic diagnosis of Wilson's Disease

    Other: No intervention

  • Asymptomatic Wilson's Disease carriers

    Other: No intervention

  • Relatives of Wilson's Disease patients or carriers

    Other: No intervention

  • Unrelated healthy controls

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. The change of Unified Wilson's Disease Rating Scale (UWDRS)

    Disease severity will be assessed by application of the Unified Wilson's Disease Rating Scale (UWDRS), a clinical rating scale consists of three subscales. Higher UWDRS total scores indicate more severe disease.

    Time frame: Up to 30years

07

Study locations

1 of 1 sites recruiting
  • First Affiliated Hospital of Fujian Medical University
    Fuzhou, China
    Recruiting
    • Jin He, MD · Contact
    • · Contacthejinfjmu@hotmail.com · 86-0591-87982772
    • Wan-Jin Chen, MD, PhD · Principal investigator
    • Ning Wanf, MD,PhD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2019 (actual). Primary completion is estimated for Dec 2039, 245 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2019
First posted
Jul 9, 2019
StartActual
Jul 1, 2019
Primary completionEst.
Dec 2039
CompletionEst.
Dec 2049
Last update
Sep 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04012658
Lead sponsor
Wan-Jin Chen
Responsible party
Wan-Jin Chen (The Vice-Director for the Department of Neurology, First Affiliated Hospital of Fujian Medical University) — Sponsor-investigator
First posted
Jul 9, 2019
Start date
Jul 1, 2019
Primary completion
Dec 2039 (estimated)
Completion
Dec 2049 (estimated)
Last update
Sep 23, 2019

Study contacts

Jin He, MD
Contact
hejinfjmu@hotmail.com
86-0591-87982772
Yi Lin, MD.PhD
Contact
linyi7811@163.com
8613615039153

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion